aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Tango Therapeutics, founded in Cambridge, United States, is a biotechnology company dedicated to discovering and developing novel medicines that target cancer vulnerabilities. The company's core mission is to deliver transformational new therapies for cancer patients by leveraging the principle of synthetic lethality. Tango Therapeutics focuses on genetically targeted therapies, aiming to provide more effective and personalized treatment options for specific tumor types.
Notable figures affiliated with Tango Therapeutics include its bold leadership and passionate team, who bring extensive expertise in oncology and drug development. The company has built a robust pipeline of potential therapies and has garnered significant attention from investors in the biotech sector. Tango Therapeutics' innovative approach and commitment to patient-centered research have positioned it as a promising player in the fight against cancer, with the potential to make a substantial impact on patient outcomes.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private Equity
Main Product(s)
Cancer Therapies
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Tango Therapeutics founded?
Tango Therapeutics was founded in 2017.
Where is Tango Therapeutics’s headquarters located?
Tango Therapeutics’s headquarters is located in Cambridge, MA, US.
When was Tango Therapeutics’s last funding round?
Tango Therapeutics’s most recent funding round was for $186M (USD) in August 2021.
How many employees does Tango Therapeutics have?
Tango Therapeutics has 110 employees as of Feb 6, 2024.
How much has Tango Therapeutics raised to-date?
As of July 05, 2023, Tango Therapeutics has raised a total of $351M (USD) since Aug 11, 2021.
Add Comparison
Total Raised to Date
$351M
USD
Last Update Aug 11, 2021
Last Deal Details
$186M
USD
Aug 11, 2021
Post Ipo Equity
Total Employees Over Time
110
As of Feb 2024
Tango Therapeutics Address
11 Hurley Street
Cambridge,
Massachusetts
02141-2110
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts